Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Cytokine. 2017 Sep 30;103:114–120. doi: 10.1016/j.cyto.2017.09.018

Figure 3. Effects of the Jak Inhibitor Ruxolitinib on IL-13-mediated Potentiation of Oxidative Stress-Induced Cell Death.

Figure 3

(A) MN9D cells were treated with 1–10 μM ruxolitinib for 60 min prior to the addition of 10 ng/ml IL-13 for 60 min. Cell lysates were prepared and equal amounts of protein were analyzed by SDS-PAGE and immunoblotting with antibodies to phospho and total Stat6. A representative Western blot is shown. Similar results were obtained in 2 independent experiments. (B) MN9D cells grown in 96 well dishes were untreated or treated with 1, 5 or 10 ng/ml IL-13 alone or in the presence of 80 μM H2O2, 2.5 μM tBOOH, 10 μM ruxolitinib or a combination as indicated. Cell survival was measured after 24 hr with the MTT assay. Results are presented as the fold change in cell death as compared to H2O2 or tBOOH alone. The experiments were done in quadruplicate and repeated 4 times. * p < 0.05; ** p < 0.01 relative to no ruxolitinib.